{"id":"NCT03481660","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","officialTitle":"A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-27","primaryCompletion":"2020-06-29","completion":"2021-06-08","firstPosted":"2018-03-29","resultsPosted":"2024-01-05","lastUpdate":"2025-01-07"},"enrollment":360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DRUG","name":"Brolucizumab","otherNames":["RTH258, ESBA1008"]},{"type":"DRUG","name":"Aflibercept","otherNames":["Eylea"]}],"arms":[{"label":"Brolucizumab 6 mg","type":"EXPERIMENTAL"},{"label":"Aflibercept 2 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This was a Phase III, randomized, double-masked, multi-center, active-controlled, two-arm study designed to evaluate the efficacy and safety of brolucizumab 6 mg compared to the active control, aflibercept 2 mg used per authorized label, in subjects with visual impairment due to diabetic macular edema (DME).","primaryOutcome":{"measure":"Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 for the Study Eye","timeFrame":"Baseline, Week 52","effectByArm":[{"arm":"Brolucizumab 6 mg","deltaMin":10.6,"sd":null},{"arm":"Aflibercept 2 mg","deltaMin":9.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":78,"countries":["Belgium","Bulgaria","Czechia","Denmark","Estonia","France","Germany","Hungary","India","Latvia","Lebanon","Lithuania","Malaysia","Norway","Poland","Russia","Singapore","Slovakia","South Korea","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":179},"commonTop":["Diabetic retinal oedema - Fellow eye","Nasopharyngitis","Hypertension","Cataract - Study eye","Cataract - Fellow eye"]}}